The first opioid case to go trial has just concluded in Oklahoma with J&J as the sole defendant. This case is important for all life science companies because of its approach to the concept of public nuisance and the fact that liability may now extend past the final manufacturer to other companies in the product supply chain (e.g., active pharmaceutical ingredient manufacturers). This article provides a detailed review of the case.
To read the full article https://complianceupdate.policymed.com/september-2019-policy-medicine-compliance-update/